Functioning and neurocognition in very early and early-life onset bipolar disorders: the moderating role of bipolar disorder type.
Eur Child Adolesc Psychiatry. 2024-05-03; :
DOI: 10.1007/s00787-024-02372-3
Read on PubMed
1. Eur Child Adolesc Psychiatry. 2024 May 3. doi: 10.1007/s00787-024-02372-3.
Online ahead of print.
Functioning and neurocognition in very early and early-life onset bipolar
disorders: the moderating role of bipolar disorder type.
Sleurs D(1)(2)(3), Speranza M(4)(5)(6)(7)(8), Etain B(4)(9)(10), Aouizerate
B(4)(11), Aubin V(4)(12), Bellivier F(4)(9)(10), Belzeaux R(4)(13)(14),
Carminati M(4)(9)(10), Courtet P(4)(15)(16), Dubertret C(4)(17)(18), Fredembach
B(4)(19), Haffen E(4)(20)(21), Groppi F(4)(13)(14), Laurent P(4)(17)(18),
Leboyer M(4)(22)(23), Llorca PM(4)(24)(25), Olié E(4)(19), Polosan M(4)(26),
Schwan R(4)(26), Weill D(4)(22)(23); FACE-B. D. (FondaMental Academic Centers of
Expertise for Bipolar Disorders) Group*; Passerieux C(4)(6)(7)(8)(27), Roux
P(4)(6)(7)(8)(27).
Author information:
(1)Fondation FondaMental, Créteil, France. .
(2)AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de
Psychiatrie Et Addictologie, Hopital Louis Mourier, 178 Rue Des Renouillers,
92700, Colombes, France. .
(3)Inserm U1266, Faculté de Médecine, Université Paris Cité, Paris, France.
.
(4)Fondation FondaMental, Créteil, France.
(5)Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie de
L’Enfant Et de L’Adolescent, Le Chesnay, France.
(6)Université Paris-Saclay, Paris, France.
(7)Université de Versailles Saint-Quentin-En-Yvelines, Versailles, France.
(8)DisAP-DevPsy-CESP, INSERM UMR1018, Villejuif, France.
(9)AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU Neurosciences,
Département de Psychiatrie Et de Médecine Addictologique, Hôpital Fernand Widal,
Paris, France.
(10)INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie
OTeN, Université Paris Cité, Paris, France.
(11)Laboratoire NutriNeuro (UMR INRA 1286), Centre Hospitalier Charles Perrens,
Université de Bordeaux, Bordeaux, France.
(12)Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco, France.
(13)Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille,
France.
(14)INT-UMR7289, CNRS Aix-Marseille Université, Marseille, France.
(15)Department of Emergency Psychiatry and Acute Care, CHU Montpellier,
Montpellier, France.
(16)IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France.
(17)AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de
Psychiatrie Et Addictologie, Hopital Louis Mourier, 178 Rue Des Renouillers,
92700, Colombes, France.
(18)Inserm U1266, Faculté de Médecine, Université Paris Cité, Paris, France.
(19)Grenoble Institut Des Neurosciences (GIN), Université Grenoble Alpes, CHU de
Grenoble Et Des Alpes, Inserm U 1216, Grenoble, France.
(20)Département de Psychiatrie Clinique, CIC-1431 INSERM, CHU de Besançon,
Besançon, France.
(21)EA481 Neurosciences, Université Bourgogne Franche-Comté, Besançon, France.
(22)Translational NeuroPsychiatry Laboratory, Univ Paris Est Créteil, INSERM
U955, IMRB, Créteil, France.
(23)AP-HP, Hôpitaux Universitaires Henri Mondor, Département
Médico-Universitaire de Psychiatrie Et d’Addictologie (DMU IMPACT), Fédération
Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT),
Créteil, France.
(24)Département de Psychiatrie, Centre Hospitalier Et Universitaire,
Clermont-Ferrand, France.
(25)Université d’Auvergne, EA 7280, 63000, Clermont-Ferrand, France.
(26)Centre Psychothérapique de Nancy, Université de Lorraine , Inserm U1254,
Nancy, France.
(27)Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie
d’Adultes Et d’Addictologie, Le Chesnay, France.
Defining homogeneous subgroups of bipolar disorder (BD) is a major goal in
personalized psychiatry and research. According to the neurodevelopmental
theory, age at onset may be a key variable. As potential trait markers of
neurodevelopment, cognitive and functional impairment should be greater in the
early form of the disease, particularly type 1 BD (BD I). The age at onset was
assessed in a multicenter, observational sample of 4190 outpatients with BD. We
used a battery of neuropsychological tests to assess six domains of cognition.
Functioning was measured using the Functioning Assessment Short Test (FAST). We
studied the potential moderation of the type of BD on the associations between
the age at onset and cognitive and functioning in a subsample of 2072 euthymic
participants, controlling for potential clinical and socio-demographic
covariates. Multivariable analyses showed cognition to not be impaired in
individuals with early (21-30 years) and very early-life (before 14 years) onset
of BD. Functioning was equivalent between individuals with early and
midlife-onset of BD II and NOS but better for individuals with early onset of BD
I. In contrast, functioning was not worse in individuals with very early-onset
BD I but worse in those with very early-onset BD II and NOS. Early-life onset
BDs were not characterized by poorer cognition and functioning. Our results do
not support the neurodevelopmental view that a worse cognitive prognosis
characterizes early-life onset BD. This study suggests that functional
remediation may be prioritized for individuals with midlife-onset BD I and very
early life onset BD 2 and NOS.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
DOI: 10.1007/s00787-024-02372-3
PMID: 38702455